上海医药：氨磺必利口崩片纳入国家医保目录

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Pharmaceuticals Zhongxi, has successfully negotiated for the inclusion of Amisulpride orally disintegrating tablets in the National Medical Insurance Directory [1] Group 1: Company Information - The Amisulpride orally disintegrating tablets are an improved formulation of the Amisulpride tablets launched by Sanofi in France in 1986 [1] - The drug is indicated for the treatment of adult schizophrenia [1] Group 2: Industry Impact - The inclusion of Amisulpride in the National Medical Insurance Directory may enhance its market accessibility and potentially increase sales [1]